Various clinical studies have correlated high circulating IL-6 levels in patients with malignant tumors, as for breast cancer [12,13], prostate cancer [14], head and neck squamous cell carcinoma [15] or renal cancer [16]. This evidence concerns the gene IL6 and prostate cancer.